Thymosin Alpha-1 and TB-500: Two Thymosins That Are Not Interchangeable
Product Guides·October 5, 2026·19 min read·99 Purity Peptides Research Team

Thymosin Alpha-1 and TB-500: Two Thymosins That Are Not Interchangeable

Quick Answer: No. Thymosin alpha-1 and TB-500 are different molecules from different precursor proteins: thymosin alpha-1 is the 28-residue N-terminal fragment of prothymosin alpha, while thymosin beta-4 — the molecule TB-500 is named after — is a separate 43-residue protein. The one identity check that settles a vial's contents is mass spectrometry on the certificate of analysis, matched to the expected mass.

Key Takeaways

  • Different molecules, different genes. Thymosin alpha-1 is a 28-residue peptide (average mass ~3,108 Da) cleaved from prothymosin alpha; thymosin beta-4 is a 43-residue acetylated protein (average mass ~4,963 Da) encoded by the TMSB4X gene. They share no precursor and no sequence.
  • "TB-500" is a trade name, not a curated chemical identity. PubChem's record for the 43-residue acetylated thymosin beta-4 (timbetasin, CID 16132341) does not list "TB-500" among its synonyms. Listings use the name for two different things: the full 43-residue peptide and a 7-residue fragment (Ac-LKKTETQ).
  • The mass gap is the whole story. The 43-residue form is ~4,963 Da; the heptapeptide fragment is ~889 Da. A mass-spectrometry identity check on the COA distinguishes them unambiguously — a purity percentage alone cannot.
  • Neither compound is FDA-approved. Thymosin alpha-1 (thymalfasin) holds FDA orphan-drug designations only; the FDA's July 2026 advisory committee reviewed TB-500 for the 503A compounding bulks list, with FDA staff proposing against inclusion.
  • Sport status is explicit. The WADA 2026 Prohibited List bans "Thymosin-β4 and its derivatives e.g. TB-500" under section S2.3.

Research Use Only. This article is about chemical identity — what these molecules are, where their names come from, and how to verify which one is in a vial. Nothing sold on this site is for human or veterinary consumption, and nothing here is medical, dosing, or health advice. No comparison of effects in any person is made or implied.

Are Thymosin Alpha-1 and TB-500 the Same Molecule?

No — they denote two different molecules. The "thymosin alpha-1 vs tb-500" query usually comes from a reader looking at two listings and wondering whether the names denote one compound or two. Thymosin alpha-1 is a 28-residue peptide with an average mass of about 3,108 Da, recorded on PubChem as CID 16130571 (thymalfasin), with the N-acetylated sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN [1]. Thymosin beta-4 — the endogenous molecule that the trade name "TB-500" refers to — is a 43-residue N-acetylated protein with an average mass of about 4,963 Da, recorded on PubChem as CID 16132341 (timbetasin), with the sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES [2].

The two sequences share no meaningful overlap. Align them and the difference is visible at a glance: thymosin alpha-1 begins Ac-SDAAVDTSSE…, thymosin beta-4 begins Ac-SDKPDMAEIE…. They are not variants of one another, not different salt forms of one compound, and not interchangeable names for a single substance. The confusion is purely nominal — both names contain the word "thymosin" — and the rest of this article is about why that word is a trap and how the primary record resolves it.

What Is the Precursor of Each Compound?

Each compound comes from its own unrelated precursor, which is the deepest reason they cannot be the same molecule.

Thymosin alpha-1 is cleaved from prothymosin alpha. Thymosin alpha-1 is synthesized as the N-terminal moiety of prothymosin alpha (ProTα), a highly acidic nuclear protein, and is released as the N-terminally acetylated 28-residue peptide by cleavage via the lysosomal asparaginyl endopeptidase legumain [3]. A review of prothymosin-alpha biology lists the fragment explicitly as "ProTα(1–28), referred to as 'Tα1'" [4]. In other words, thymosin alpha-1 is literally the first 28 amino acids of a larger, well-characterized precursor protein.

Thymosin beta-4 is the product of a separate gene. In humans, thymosin beta-4 is encoded by the TMSB4X gene on the X chromosome (Entrez Gene ID 7114), whose reference protein maps to UniProtKB accession P62328 [5][6]. It has no precursor relationship to prothymosin alpha whatsoever. The UniProt canonical sequence is 44 residues including the initiator methionine (MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, ~5,053 Da); the mature, biologically isolated form lacks the initiator methionine and carries an N-terminal acetyl group, giving the 43-residue acetylated peptide recorded on PubChem [2][7].

Two different genes, two different precursor proteins, two different processing pathways. Nothing about the "thymosin" prefix overrides that.

What Does the Primary Record Say Each Molecule Is?

The table below gives the identity of each molecule exactly as the curated records state it. Every number is traced to its source; where the record is silent, the cell says so.

Thymosin alpha-1

Thymosin beta-4 (mature, acetylated form)

Precursor protein / gene

Prothymosin alpha (N-terminal residues 1–28), released by legumain cleavage [3][4]

TMSB4X gene product, UniProt P62328 (mature chain = residues 2–44) [5][6]

Residue count

28 [1]

43 [2]

Sequence (N→C)

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN [1]

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES [2]

Average mass

3,108.3 g/mol [1]

4,963 g/mol [2]

Monoisotopic mass

3,106.5041 Da [1]

4,960.4863 Da [2]

Molecular formula

C129H215N33O55 [1]

C212H350N56O78S [2]

CAS number

62304-98-7 [1]

77591-33-4 [2]

Regulatory synonym

Thymalfasin (INN/USAN) [1]

Timbetasin (INN/USAN) [2]

Table 1. Identity of the two molecules from curated records. [1] = PubChem CID 16130571, read directly October 2026. [2] = PubChem CID 16132341, read directly October 2026.

Two footnotes matter. First, the "43 vs 44" residue question for thymosin beta-4: the UniProt canonical entry P62328 includes the initiator methionine (44 residues, 5,053 Da), while the mature N-acetylated chain isolated from tissue — and the synthetic material described in listings — is 43 residues (4,963 Da) [2][7]. Both numbers are correct; they describe different forms. Listings that quote a single mass without saying which form they mean are the source of half the confusion in this space.

Second, the INN names: the WHO-recommended international nonproprietary name for synthetic thymosin alpha-1 is thymalfasin, and for thymosin beta-4 it is timbetasin (recommended 2018) [1][8]. These are the names under which the substances would appear in any future drug regulatory context — not "TB-500," which appears in neither INN list.

What Is Actually Sold Under the Name "TB-500"?

This is the honest center of the article, because the primary record does not give a single clean answer — and saying so is the information gain.

What the curated record says: PubChem's compound page for the 43-residue acetylated thymosin beta-4 (CID 16132341, titled "Timbetasin") was read in full in October 2026. Its depositor-supplied synonym list includes "Timbetasin," "Thymosin beta4," "Fx Peptide," "Tbeta4," and the CAS number 77591-33-4 — but not "TB-500" or "TB500" [2]. The trade name simply does not appear in the curated record for the full-length molecule. That absence is itself a finding: "TB-500" is a market label, not a synonym recognized by the chemical databases.

What the name is used to mean: Across listings and comparison pages, "TB-500" is applied to two different chemical identities, summarized below.

Candidate identity

Description

Average mass

What the record says

43-residue acetylated thymosin beta-4

Full-length synthetic copy of the mature protein: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

~4,963 Da (PubChem CID 16132341) [2]

The molecule most listings describe; PubChem does not list "TB-500" as a synonym

7-residue fragment Ac-LKKTETQ

N-acetylated heptapeptide matching residues 17–23 of thymosin beta-4 (the actin-binding motif)

~889 Da (calculated from the sequence Ac-LKKTETQ, C38H68N10O14)

Described as TB-500 in encyclopedic and some listing sources [9]; no curated database entry under the TB-500 name was found

Table 2. The two chemical identities marketed under the name "TB-500." The ~5.6-fold mass difference is what a mass-spec identity check resolves.

The practical consequence: a vial labeled "TB-500" could contain a ~4,963 Da peptide or a ~889 Da peptide depending on which identity the seller synthesized — and the label alone does not tell you which. This is not a theoretical concern; it is the single most important identity fact in this article, and it is why the COA identity check below is written the way it is.

What the FDA record says: The FDA's briefing document for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting lists "TB-500-related bulk drug substances (TB-500 (free base)/TB-500 acetate)" as nominated for the 503A bulks list, nominated by Wells Pharmacy Network — but the document gives no chemical definition, sequence, or mass for the substance [10]. FDA staff proposed that neither form be included on the bulks list [10]. So the federal regulatory record, too, uses the name without pinning down the molecule.

Why Do Listings Confuse the Two Names?

The confusion has a traceable history, and it comes down to one word: "thymosin."

In the 1960s–70s, researchers fractionated calf thymus extracts and named the biologically active fractions "thymosin fraction 5." The components were numbered — thymosin alpha-1, thymosin beta-4, and others — by fractionation order, not by chemical relationship. As later work established, these are "structurally and genetically unrelated" proteins that merely co-purified from thymic tissue; beta-thymosins are a family of ~40-residue actin-binding proteins found in many tissues, with no structural relationship to the alpha-thymosins [11].

That historical accident is still doing damage. "Thymosin" in a product name sounds like it identifies a single chemical family, the way "penicillin" does. It does not. The name table makes the tangle visible:

Name

What it actually is

Relationship to the other column

Thymosin alpha-1

28-aa peptide from prothymosin alpha

None — different precursor, sequence, mass

Thymalfasin

INN/USAN for synthetic thymosin alpha-1

Same molecule as thymosin alpha-1 [1]

Thymosin beta-4

43-aa (mature) protein from TMSB4X

None — different precursor, sequence, mass

Timbetasin

INN/USAN for thymosin beta-4

Same molecule as thymosin beta-4 [2][8]

TB-500

Trade name applied to either the 43-aa peptide or the 7-aa fragment

Ambiguous — the name does not identify one molecule [2][9]

Table 3. The names that get tangled, and what each one actually denotes.

Two habits keep the tangle alive in listings. First, vendors describe TB-500 as "a fragment of thymosin beta-4" while simultaneously giving the full 43-residue sequence and the 4,963 Da mass — using "fragment" loosely to mean "synthetic copy" rather than "shorter piece." Second, other listings use "TB-500" for the actual 7-residue fragment, sometimes quoting masses in the ~840 Da range that match neither the verified 43-mer (4,963 Da) nor the calculated acetylated heptapeptide (889 Da) precisely. Neither habit is anchored in a curated record, which is why this article anchors every number to PubChem instead.

How Can You Tell Which Thymosin Is in a Vial?

By reading the certificate of analysis the way it is meant to be read: as an identity document first and a purity report second. Our full walkthrough is here: How to Read a Certificate of Analysis (COA): A Complete Guide. The short version, specific to these two compounds:

COA field

What it confirms

What to look for

Identity by mass spectrometry

That the material in the vial has the expected molecular mass

A measured mass matching ~3,108 Da (thymosin alpha-1) or ~4,963 Da (43-residue thymosin beta-4) — or ~889 Da if the material is the Ac-LKKTETQ fragment. A mass near 3,108 in a vial labeled "TB-500" means the vial contains thymosin alpha-1, not TB-500 in any sense

Sequence confirmation

That the residue order matches the label

The 28-residue or 43-residue sequence from Table 1, including the N-terminal acetyl group

Purity (HPLC)

How much of the material is the stated compound vs. impurities

Useful only after identity is confirmed — a 99% pure vial of the wrong peptide is still the wrong peptide

Net peptide content

How much actual peptide is present vs. salts and water

Relevant to quantity, not identity

Table 4. The COA identity check for thymosin compounds: mass spectrometry first, purity second.

The one identity check a reader can run, stated plainly: find the mass-spec identity line on the COA, read the measured mass, and compare it to the three reference masses above. If the measured mass is ~3,108 Da, the vial holds thymosin alpha-1 regardless of what the label says. If it is ~4,963 Da, it holds the full-length thymosin beta-4 form. If it is ~889 Da, it holds the heptapeptide fragment. Purity percentages, appearance descriptions, and product names cannot substitute for this check — and a COA that reports purity without any mass-spec or sequence identity data has not confirmed identity at all.

Is Thymalfasin the Same as Thymosin Alpha-1?

Yes. Thymalfasin is the INN/USAN (international nonproprietary / United States adopted name) for the synthetic version of thymosin alpha-1, and PubChem describes it as "a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1" [1]. The two names denote the same 28-residue, N-acetylated molecule (CAS 62304-98-7). "Thymalfasin" is the name used in drug-regulatory contexts; "thymosin alpha-1" is the name used in research contexts. There is no chemical difference between them — unlike "TB-500," which, as shown above, does not map to one molecule at all.

Is TB-500 FDA-Approved?

No. TB-500 is not an FDA-approved drug, and it does not appear on the FDA's list of approved products. Its most recent federal regulatory appearance was the July 23–24, 2026 meeting of the FDA's Pharmacy Compounding Advisory Committee, which considered "TB-500 (free base)" and "TB-500 acetate" as bulk drug substances nominated for the 503A compounding bulks list; FDA staff proposed that neither form be added to the list [10]. A nomination for the compounding bulks list is not an approval, and the staff recommendation ran against inclusion. Material sold under the TB-500 name in the research-chemical market is sold for research use, not as an approved medicine.

Is Thymosin Alpha-1 Approved Outside the US?

The count most often repeated — "dozens of countries" — traces to a single descriptive line. PubChem's description of thymalfasin states that "Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C" [1]; the same line appears in the THPdb therapeutic-peptide database entry for thymalfasin [12]. This article could not independently verify the individual country approvals behind that figure from regulator pages, so the number is reported here as attributed to those databases, not as an independently confirmed count.

What is independently confirmed is the US status: the FDA's orphan-drug database lists thymalfasin as designated (not approved) for chronic active hepatitis B (designated May 3, 1991) and for hepatocellular carcinoma (designated March 6, 2000), with the approval status field reading "Not FDA Approved for Orphan Indication" in both entries [13][14]. Designation is an incentive status for development; it is not an approval.

Are Thymosin Peptides Banned in Sport?

For thymosin beta-4 and its derivatives, the answer is written into the WADA 2026 Prohibited List. Under section S2.3, "Growth Factors and Growth Factor Modulators," the list prohibits, "including, but not limited to," a series of growth factors — and names explicitly: "Thymosin-β4 and its derivatives e.g. TB-500" [15]. That is a direct quote from the official list. Athletes subject to WADA-code testing should treat both the full-length molecule and anything sold as TB-500 as prohibited. (Thymosin alpha-1 is not named in that entry.)

What Do the COVID-19 Thymosin Studies Show?

Thymosin alpha-1 appears in the COVID-19 literature, and the findings point in more than one direction — which is precisely why they are summarized here with their designs attached, and not presented as evidence for any use.

The most-cited study is a retrospective review by Liu et al. of 76 severe COVID-19 cases admitted to two hospitals in Wuhan from December 2019 to March 2020 (PubMed PMID 32442287) [16]. Compared with the untreated group, the thymosin alpha-1 treated group had lower mortality (11.11% vs. 30.00%, p = 0.044), alongside restored T-cell counts in severely lymphocytopenic patients and reduced exhaustion markers (PD-1, Tim-3) on CD8+ T cells [16]. That is a retrospective, non-randomized comparison of 76 patients — a design that can show association, not causation, and the authors' own framing is mechanistic (thymus output, T-cell exhaustion reversal) rather than a treatment claim.

The later literature does not uniformly agree. A 2022 analysis reported that thymosin alpha-1 use was not associated with reduced COVID-19 mortality [17], and a 2021 cohort study found no beneficial effect of thymosin alpha-1 on restoring CD4+ and CD8+ T-lymphocyte counts in COVID-19 patients [18]. A 2023 systematic review and meta-analysis of thymosin alpha-1 in moderate-to-critical COVID-19 found a possible mortality association influenced by sample size and sex, while calling for further randomized trials with proper methodology [19].

The honest summary: one small retrospective study reported a mortality difference favoring thymosin alpha-1; subsequent studies did not reproduce it; the evidence base is observational, conflicting, and insufficient to establish anything about use. That is all the primary record supports, and this article claims nothing beyond it.

Which Listing Claims Do Not Survive the Primary Record?

Vendor comparison pages for these compounds disagree with each other on basic numbers. Checked against the curated records, several recurring claims fail. No vendor is named; the corrections are what matter.

Claim found in listings

What the primary record says

"TB-500 is a synthetic seven-residue fragment at about 839 Da" (stated as settled fact)

The curated record for the 43-residue molecule most "TB-500" listings describe gives 4,963 g/mol [2]. The acetylated heptapeptide Ac-LKKTETQ calculates to ~889 Da average mass. The ~839 Da figure matches neither; it is an unsourced listing figure. State which of the two candidate identities you mean before quoting a mass.

"TB-500 is simply synthetic thymosin beta-4" (stated as a settled identity)

PubChem's record for acetylated thymosin beta-4 does not list "TB-500" as a synonym (full synonym list checked October 2026) [2]. The name is a trade label applied to two different molecules (Table 2).

"Thymosin beta-4 has a molecular weight of [single number]" (no form specified)

The UniProt canonical sequence (P62328, with initiator methionine) is 44 residues at ~5,053 Da; the mature N-acetylated chain is 43 residues at ~4,963 Da [2][7]. A mass without a specified form is not verifiable.

"Thymalfasin is FDA-approved"

FDA orphan-drug database: designated for two indications, "Not FDA Approved for Orphan Indication" in both [13][14].

"Thymosin alpha-1 and TB-500 are interchangeable because both are thymosins"

Different precursors (prothymosin alpha vs. TMSB4X), different sequences, different masses [1][2][3][6]. "Thymosin" is a historical fractionation label, not a chemical family [11].

Table 5. Recurring listing claims and their primary-record corrections.

One control worth noting: the figures most listings give for thymosin alpha-1 — 28 residues, ~3,108 Da — do survive. PubChem confirms 28 residues, 3,108.3 g/mol average mass, and the exact N-acetylated sequence [1]. When a listing gets thymosin alpha-1's numbers right and TB-500's numbers wrong, that asymmetry is itself informative about where the uncertainty lives.

What This Page Does Not Establish

This page establishes chemical identity only. It does not establish any comparison of effects, potency, or outcomes between these compounds in any person or animal. It does not establish that either compound is safe or effective for any purpose. It does not establish dosing, administration, reconstitution, or handling instructions of any kind — none are given here. The COVID-19 studies are described for what their designs support and no further. The regulatory facts (WADA listing, FDA designations, PCAC review) are status facts, not findings about the compounds' properties. Nothing in this article is medical, dosing, or health advice.

For Researchers Comparing the Two Identities

Identity is the entire subject of this page, and it is also the practical reason researchers keep the two compounds side by side: the names invite confusion, the masses settle it, and having both reference materials in hand makes the mass-spec comparison direct. The Thymosin Family Comparator bundle pairs a TB-500 5 mg vial with a thymosin alpha-1 10 mg vial as research materials with lot documentation (listed at $109.99, in stock at the time of checking). For background on each compound on its own, read the profiles for thymosin alpha-1 immune support and TB-500 tissue repair research. For how each one compares with other peptides, see the pairwise comparisons Thymosin Alpha-1 vs LL-37 and BPC-157 vs TB-500. For running the identity check described above, use the COA reading guide.

For how counterions change the amount of peptide in a vial, see peptide salt forms.

References

  1. PubChem CID 16130571 — Thymalfasin (thymosin alpha-1). Sequence, formula C129H215N33O55, average mass 3108.3 g/mol, monoisotopic mass 3106.5041 Da, CAS 62304-98-7; "chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1." https://pubchem.ncbi.nlm.nih.gov/compound/16130571
  2. PubChem CID 16132341 — Timbetasin (acetylated thymosin beta-4). Sequence SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (N-acetylated), formula C212H350N56O78S, average mass 4963 g/mol, monoisotopic mass 4960.4863 Da, CAS 77591-33-4. "TB-500"/"TB500" absent from the synonym list (checked October 2026). https://pubchem.ncbi.nlm.nih.gov/compound/16132341
  3. "PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology." Int. J. Mol. Sci. 2021, 22, 124. "Tα1 is synthesized as the N-terminal moiety of… prothymosin α (ProTα)… Cleaved by the lysosomal asparaginyl endopeptidase (legumain…), the N-terminally acetylated 28-residue peptide Tα1 gets released." https://www.mdpi.com/1422-0067/22/1/124
  4. "Prothymosin Alpha and Immune Responses." PMC (review). "proTα was the natural precursor of Tα1"; Table 1: "ProTα(1–28), referred to as 'Tα1'." https://pmc.ncbi.nlm.nih.gov/articles/PMC7126549/
  5. NCBI Gene: TMSB4X (thymosin beta 4, X-linked), Gene ID 7114; reference protein NP_066932.1 mapping to UniProtKB/Swiss-Prot P62328. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=7114
  6. "Thymosin beta-4." Wikipedia. Encoded by TMSB4X; UniProt P62328; canonical 44-aa sequence (incl. initiator Met), ~5,053 g/mol. https://en.wikipedia.org/wiki/Thymosin_beta-4
  7. CUSABIO recombinant human thymosin beta-4 (TMSB4X) datasheet: "Expression Region: 2-44aa; Full Length of Mature Protein" (UniProt P62328) — mature chain is 43 residues after initiator-methionine removal. https://www.cosmobiousa.com/content/document/cusabio/csb-ap000381hu_recombinant-human-thymosin-beta-4-tmsb4x-active-csb-ap000381hu__67366.pdf
  8. RegeneRx Biopharmaceuticals, Sept. 6, 2018: "World Health Organization Recommends INN for Thymosin Beta 4 as 'timbetasin'." http://www.regenerx.com/2018-09-06-World-Health-Organization-Recommends-INN-for-Thymosin-Beta-4-as-timbetasin
  9. "TB-500." Wikipedia. "TB-500 (Ac-LKKTETQ) is a synthetic heptapeptide that corresponds to the N-acetylated active fragment (amino acids 17–23) of… thymosin beta-4." https://en.wikipedia.org/wiki/TB-500
  10. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: "TB-500-related bulk drug substances (TB-500 (free base)/TB-500 acetate)" nominated by Wells Pharmacy Network; "FDA is proposing that TB-500 (free base) NOT be included on the 503A Bulks List" (likewise acetate). No chemical definition given. https://www.fda.gov/media/193342/download
  11. "Beta thymosins." Wikipedia. "Both thymosin α1 and β-thymosins are intrinsically unstructured proteins… Thymosin β4 was originally obtained from the thymus in company with several other small proteins which although named collectively 'thymosins' are now known to be structurally and genetically unrelated." https://en.wikipedia.org/wiki/Beta_thymosins
  12. THPdb entry Th1110 (Thymalfasin): "It is now approved in 35 developing countries for the treatment of Hepatitis B and C." http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1110
  13. FDA Orphan Drug Designations and Approvals: thymalfasin, chronic active hepatitis B, designated 05/03/1991 — "Not FDA Approved for Orphan Indication." https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=52990
  14. FDA Orphan Drug Designations and Approvals: thymalfasin, hepatocellular carcinoma, designated 03/06/2000 — "Not FDA Approved for Orphan Indication." https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=132600
  15. WADA 2026 Prohibited List, S2.3 Growth Factors and Growth Factor Modulators: "Thymosin-β4 and its derivatives e.g. TB-500." https://www.wada-ama.org/en/prohibited-list
  16. Liu Y. et al. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells." Clin. Infect. Dis. 2021, 71(16), 2150–2157. Retrospective review of 76 severe cases, 2 Wuhan hospitals, Dec 2019–Mar 2020; mortality 11.11% vs. 30.00%, p = .044. PubMed PMID 32442287. https://doi.org/10.1093/cid/ciaa630
  17. Liu T. et al. "Thymosin a1 use is not associated with reduced COVID-19 mortality." Am. J. Emerg. Med. 2022, 53, 252–253. https://doi.org/10.1016/j.ajem.2021.04.043
  18. Wang Z. et al. "Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients." Front. Immunol. 2021, 12, 568789. https://doi.org/10.3389/fimmu.2021.568789
  19. "The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression." Inflammopharmacology (Springer). Conclusion: possible mortality association influenced by sample size and sex; further randomized trials encouraged. https://doi.org/10.1007/s10787-023-01354-2

Research DisclaimerAll products across every category are for research use only and not for human or veterinary use, diagnosis or treatment.

Frequently Asked Questions

Are thymosin alpha-1 and TB-500 the same?

No. Thymosin alpha-1 is a 28-residue peptide (about 3,108 Da) cleaved from prothymosin alpha. TB-500 is a trade name associated with thymosin beta-4, a separate 43-residue acetylated protein (about 4,963 Da) encoded by the TMSB4X gene. The two share no precursor, no sequence, and no mass — only the historical "thymosin" naming label.

What is TB-500?

TB-500 is a trade name, not a curated chemical identity. It is most often used for material described as synthetic thymosin beta-4 (the 43-residue acetylated peptide, ~4,963 Da), but some sources use it for Ac-LKKTETQ, a 7-residue fragment (~889 Da). Because the name covers two different molecules, only a mass-spec identity check on the COA can say which one is in a given vial. PubChem's record for acetylated thymosin beta-4 does not list "TB-500" as a synonym, and the FDA's 2026 compounding review named the substance without defining it chemically.

What is thymosin alpha-1?

Thymosin alpha-1 is a 28-residue, N-terminally acetylated peptide (average mass 3,108.3 Da, formula C129H215N33O55) that constitutes the first 28 amino acids of the precursor protein prothymosin alpha, released by legumain cleavage. Its sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. The synthetic version's regulatory name is thymalfasin. PubChem records it as CID 16130571 with the full structure, masses, and identifiers verified.

Is TB-500 the same as thymosin beta-4?

Not exactly. Most listings use "TB-500" to mean synthetic thymosin beta-4 (the 43-residue acetylated form), but PubChem's record for that molecule (timbetasin, CID 16132341) does not list "TB-500" as a synonym, and other sources apply the name to the 7-residue Ac-LKKTETQ fragment. "TB-500 = thymosin beta-4" is a market convention, not a database-backed identity. Treat the name as a label to be verified by mass spectrometry, not as a chemical definition.

Where does thymosin alpha-1 come from in the body?

Thymosin alpha-1 is produced as the N-terminal 28-residue portion of prothymosin alpha, a highly acidic protein, and is released by cleavage carried out by the lysosomal enzyme legumain (asparaginyl endopeptidase). It was first isolated from thymic tissue — hence the name — but the precursor protein is expressed more broadly. The key identity fact is the precursor relationship: thymosin alpha-1 is ProTα residues 1–28, N-terminally acetylated.

Why do listings confuse the two names?

Because "thymosin" is a historical fractionation label, not a chemical family name. In the 1960s–70s, calf thymus extracts were separated into "thymosin fraction 5" and its components numbered alpha-1, beta-4, and others by separation order. Later work showed these are structurally and genetically unrelated proteins that merely co-purified. Listings inherit the old naming and present the compounds as relatives; the primary record shows different precursors, sequences, and masses.

What molecular weight does thymosin alpha-1 have?

Thymosin alpha-1 has an average molecular mass of 3,108.3 g/mol (monoisotopic mass 3,106.5041 Da, exact mass 3,107.5075 Da), per PubChem CID 16130571. Its molecular formula is C129H215N33O55 and its CAS number is 62304-98-7. These figures describe the N-acetylated 28-residue peptide; they are among the few listing figures that fully survive checking against the curated record.

How can I tell which thymosin is in a vial?

Read the mass-spectrometry identity line on the certificate of analysis and compare the measured mass to the reference masses: ~3,108 Da indicates thymosin alpha-1, ~4,963 Da the full-length thymosin beta-4 form, and ~889 Da the Ac-LKKTETQ fragment. A COA without mass-spec or sequence identity data has not confirmed identity — see the COA reading guide. Purity percentages cannot distinguish the compounds — a 99% pure vial of the wrong peptide is still the wrong peptide.

Is thymalfasin the same as thymosin alpha-1?

Yes. Thymalfasin is the INN/USAN regulatory name for synthetic thymosin alpha-1, which PubChem describes as chemically identical to the human peptide. Both names denote the same 28-residue N-acetylated molecule (CAS 62304-98-7, ~3,108 Da). "Thymalfasin" appears in drug-regulatory contexts; "thymosin alpha-1" in research contexts. This is a genuine synonym pair — unlike "TB-500," which maps to no single molecule in the curated record.

Is TB-500 FDA-approved?

No. TB-500 is not an FDA-approved drug. Its most recent federal regulatory appearance was the FDA Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, where "TB-500 (free base)" and "TB-500 acetate" were considered as nominated 503A bulks-list substances; FDA staff proposed that neither be included. A bulks-list nomination is not an approval, and material sold as TB-500 remains a research chemical, not an approved medicine.

Is thymosin alpha-1 approved outside the US?

PubChem's description of thymalfasin states it is "approved in 35 developing countries for the treatment of Hepatitis B and C," a line also carried by the THPdb database. This article could not independently verify the individual country approvals behind that figure, so it is reported as attributed to those databases. In the US, the FDA has granted orphan-drug designations only (chronic active hepatitis B, 1991; hepatocellular carcinoma, 2000), with both entries marked "Not FDA Approved for Orphan Indication".

Are thymosin peptides banned in sport?

Thymosin beta-4 and its derivatives are explicitly prohibited. The WADA 2026 Prohibited List, section S2.3 ("Growth Factors and Growth Factor Modulators"), bans "Thymosin-β4 and its derivatives e.g. TB-500" — a direct quote from the official list. Thymosin alpha-1 is not named in that entry. Athletes subject to WADA-code testing should treat thymosin beta-4 and anything sold as TB-500 as prohibited substances.

What does a COA identity check look like?

A proper identity check has three visible elements on the certificate of analysis: (1) a mass-spectrometry result matched against the expected mass (~3,108 Da for thymosin alpha-1, ~4,963 Da for full-length thymosin beta-4, ~889 Da for the fragment); (2) sequence confirmation including the N-terminal acetyl group; and (3) a batch-specific lot number tying the document to the vial. HPLC purity percentage, appearance notes, and product names are not identity confirmation. See the COA reading guide for the full walkthrough.

Do the COVID-19 thymosin studies show a benefit?

The evidence is mixed and observational. A 2020 retrospective review of 76 severe COVID-19 cases (PubMed PMID 32442287) reported lower mortality in the treated group (11.11% vs. 30.00%, p = 0.044), but retrospective designs show association, not causation. A 2022 analysis found no mortality association, and a 2021 cohort study found no benefit on T-cell count restoration. A 2023 meta-analysis called for proper randomized trials. Nothing here establishes any use.

How do researchers tell these two compounds apart in a study design?

By specifying the exact molecular identity rather than the trade name: the 28-residue thymosin alpha-1 sequence (~3,108 Da) versus the 43-residue thymosin beta-4 sequence (~4,963 Da) or the Ac-LKKTETQ fragment (~889 Da), each confirmed by mass spectrometry on the lot's COA. A study design that writes "TB-500" without a sequence, CAS number, or measured mass has not defined its test article — the primary record shows the name alone is ambiguous.

Our Best Sellers

Shop Top Products

BPC-157/TB-500

Healing & Recovery Research Compounds

Buy BPC-157/TB-500 research-grade peptide blend available in 5mg/5mg and 10mg/10mg formulations. Studied for tissue regeneration, cellular signaLling, extracellular matrix biology, and recovery research. Laboratory use only.

BPC-157/TB-500
5/5mg
$80.00

KLOW

Healing & Recovery Research Compounds

Buy research-grade KLOW 50mg/10mg/10mg/10mg (3ML). Multi-compound blend studied for metabolic and receptor signaling research. Laboratory use only.

KLOW
From
$100

GLOW

Healing & Recovery Research Compounds

Buy research-grade GLOW 50mg/10mg/10mg (3ML). Multi-compound blend studied for metabolic and cellular signaling research. Laboratory use only.

GLOW
From
$85

MOTS-C

GLP-1 & Metabolic Research Compounds

Buy research-grade MOTS-C 10mg, 20mg and 40mg (3ML). Mitochondrial-derived peptide studied for cellular energy and metabolic research. Laboratory use only.

MOTS-C
10mg
$60.00

Semax / Selank (Blend)

Cognitive & Nootropic Research Compounds

Buy research-grade Semax / Selank Blend 10mg/10mg (3ML). Peptide combination studied for neuropeptide and neurotransmitter research. Laboratory use only.

Semax / Selank (Blend)
From
$90

GHK-Cu

Cosmetic & Skin Research Compounds

Buy research-grade GHK-Cu 50mg or 100mg. Copper-binding tripeptide studied for collagen and cellular signaling research. Laboratory use only.

GHK-Cu
50mg
$40.00
Related research

More on this topic

Related

Continue reading